Skip to main content
Erschienen in: Journal of Cancer Education 1/2015

01.03.2015

Impact of Primary Care Provider Knowledge, Attitudes, and Beliefs about Cancer Clinical Trials: Implications for Referral, Education and Advocacy

verfasst von: Margo Michaels, Thomas A. D’Agostino, Natasha Blakeney, Elisa S. Weiss, Maria C. Binz-Scharf, Mitch Golant, Carma L. Bylund

Erschienen in: Journal of Cancer Education | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Primary Care Providers (PCPs) can be instrumental in helping to prepare patients for referral to cancer treatment. It has been suggested that PCPs can have an important impact on priming patients about the possibility of receiving care within a cancer treatment clinical trial (CCT). However, little is understood about how to effectively engage primary care providers in educating patients about trials. Data were collected as part of two qualitative research projects about primary care providers’ role in referral to treatment and to CCTs. Participants were 27 PCPs who agreed to take part in qualitative face-to-face or telephone interviews and serve predominantly underserved, minority populations. Interviews identified a number of factors influencing referral to oncologists, including patients’ insurance coverage, location and proximity to treatment facilities, and the strength of ongoing relationships with and/or previous experience with a specialist. PCPs overwhelmingly expressed disinterest in discussing any treatment options, including CCTs. Misconceptions about quality of care received through trials were also common, presenting a deterrent to discussion. PCPs need targeted, evidence-based educational interventions to appropriately address their concerns about cancer clinical trials, enhance provider communication skills, and alter patient referral behavior. Steps must also be taken to strengthen communication between oncologists and referring PCPs.
Literatur
1.
Zurück zum Zitat American College of Surgeons: Commission on Cancer. 2009. Cancer Program Standards, revised edition. Chicago, IL American College of Surgeons: Commission on Cancer. 2009. Cancer Program Standards, revised edition. Chicago, IL
2.
Zurück zum Zitat Nass JS, Moses HL, Mendelsohn J (2010) A National Cancer Clinical Trials System for the 21st century: reinvigorating the NCI Cooperative Group Program. The National Academies Press, Washington Nass JS, Moses HL, Mendelsohn J (2010) A National Cancer Clinical Trials System for the 21st century: reinvigorating the NCI Cooperative Group Program. The National Academies Press, Washington
3.
Zurück zum Zitat Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical trials: race-, sex-, and age-based disparities. J Am Med Assoc 291:2720–2726CrossRef Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical trials: race-, sex-, and age-based disparities. J Am Med Assoc 291:2720–2726CrossRef
4.
Zurück zum Zitat Powe, Neil R., Tiffany L. Gary. 2004. Clinical trials chapter in Race and research in focus:perspectives on minority participation in health studies. Bettina M, editor. American Public Health Association Powe, Neil R., Tiffany L. Gary. 2004. Clinical trials chapter in Race and research in focus:perspectives on minority participation in health studies. Bettina M, editor. American Public Health Association
5.
Zurück zum Zitat Stewart JH, Bertoni AG, Staten JL et al (2007) Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities. Ann Surg Oncol 14:3328–3334CrossRefPubMed Stewart JH, Bertoni AG, Staten JL et al (2007) Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities. Ann Surg Oncol 14:3328–3334CrossRefPubMed
9.
Zurück zum Zitat Ford JG, Howerton MW, Bolen S et al (2005) Knowledge and access to information on recruitment of underrepresented populations to cancer clinical trials. Evidence Report Technology Assessment (Summary) 122:1–11. AHRQ Publication No. 05-E019-1. Agency for Healthcare Research and Quality, Rockville Ford JG, Howerton MW, Bolen S et al (2005) Knowledge and access to information on recruitment of underrepresented populations to cancer clinical trials. Evidence Report Technology Assessment (Summary) 122:1–11. AHRQ Publication No. 05-E019-1. Agency for Healthcare Research and Quality, Rockville
11.
Zurück zum Zitat Simon MS, Wei D, Flaherty L et al (2004) Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol 22:2046–2052CrossRefPubMed Simon MS, Wei D, Flaherty L et al (2004) Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol 22:2046–2052CrossRefPubMed
12.
Zurück zum Zitat Ford JG, Howerton MW, Lai GY et al (2008) Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer 112:228–242CrossRefPubMed Ford JG, Howerton MW, Lai GY et al (2008) Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer 112:228–242CrossRefPubMed
13.
Zurück zum Zitat David W, Kington R, Madans J et al (2006) Are racial and ethnic minorities less willing to participate in health research? PLoS Med 3:e19, Epub 2005CrossRef David W, Kington R, Madans J et al (2006) Are racial and ethnic minorities less willing to participate in health research? PLoS Med 3:e19, Epub 2005CrossRef
14.
Zurück zum Zitat Robinson MK, Tsark JAU, Braun KL (2014) Increasing primary care physician support for and promotion of cancer clinical trials. Hawai’i J Med Public Health 73:84–88 Robinson MK, Tsark JAU, Braun KL (2014) Increasing primary care physician support for and promotion of cancer clinical trials. Hawai’i J Med Public Health 73:84–88
16.
Zurück zum Zitat National Research Council (2005) From cancer patient to cancer survivor: lost in transition. The National Academies Press, Washington, DC National Research Council (2005) From cancer patient to cancer survivor: lost in transition. The National Academies Press, Washington, DC
17.
Zurück zum Zitat Crosson K, Eisner E, Brown C et al (2001) Primary care physicians’ attitudes, knowledge, and practices related to cancer clinical trials. J Cancer Educ 16:188–192PubMed Crosson K, Eisner E, Brown C et al (2001) Primary care physicians’ attitudes, knowledge, and practices related to cancer clinical trials. J Cancer Educ 16:188–192PubMed
18.
Zurück zum Zitat Chen DT, Miller FG, Rosenstein DL (2003) Clinical research and the physician-patient relationship. Annnals Intern Med 138:669–672CrossRef Chen DT, Miller FG, Rosenstein DL (2003) Clinical research and the physician-patient relationship. Annnals Intern Med 138:669–672CrossRef
20.
Zurück zum Zitat Sherwood PR, Given BA, Scholnik A et al (2004) To refer or not to refer: factors that affect primary care provider referral of patients with cancer to clinical treatment trials. J Cancer Educ 19:58–65CrossRefPubMed Sherwood PR, Given BA, Scholnik A et al (2004) To refer or not to refer: factors that affect primary care provider referral of patients with cancer to clinical treatment trials. J Cancer Educ 19:58–65CrossRefPubMed
21.
Zurück zum Zitat Bernard HR (2005) Research methods in anthropology: qualitative and quantitative approaches, 4th edn. AltaMira Press, Walnut Creek Bernard HR (2005) Research methods in anthropology: qualitative and quantitative approaches, 4th edn. AltaMira Press, Walnut Creek
22.
Zurück zum Zitat Patton MQ (2002) Qualitative research and evaluation methods, 3rd edn. Sage, Thousand Oaks Patton MQ (2002) Qualitative research and evaluation methods, 3rd edn. Sage, Thousand Oaks
23.
Zurück zum Zitat Creswell JW (1998) Qualitative inquiry and research design choosing among five traditions. Sage, Thousand Oaks Creswell JW (1998) Qualitative inquiry and research design choosing among five traditions. Sage, Thousand Oaks
24.
Zurück zum Zitat Miles MB, Huberman AM (1994) Qualitative data analysis: an expanded sourcebook, 2nd ed. Sage, Thousand Oaks Miles MB, Huberman AM (1994) Qualitative data analysis: an expanded sourcebook, 2nd ed. Sage, Thousand Oaks
Metadaten
Titel
Impact of Primary Care Provider Knowledge, Attitudes, and Beliefs about Cancer Clinical Trials: Implications for Referral, Education and Advocacy
verfasst von
Margo Michaels
Thomas A. D’Agostino
Natasha Blakeney
Elisa S. Weiss
Maria C. Binz-Scharf
Mitch Golant
Carma L. Bylund
Publikationsdatum
01.03.2015
Verlag
Springer US
Erschienen in
Journal of Cancer Education / Ausgabe 1/2015
Print ISSN: 0885-8195
Elektronische ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-014-0662-6

Weitere Artikel der Ausgabe 1/2015

Journal of Cancer Education 1/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.